Charlie Gard's parents pressed for new evidence to allow treatment overseas

London hospital reviews ending baby's life support

Charlie's parents, Chris Gard and Connie Yates, have until Wednesday to submit new written evidence regarding the viability of having Charlie treated overseas with experimental nucleoside therapy.

There is lab evidence that the experimental treatment protocol for Charlie prepared by the Bambino Gesu' may work, according to a letter from Rome to London's Great Ormond Street Hospital which on Friday officially asked its doctors to be allowed to administer it. Mr Gard yelled at a barrister representing Great Ormond Street bosses, saying: "When are you going to start telling the truth?"

The small Charlie suffers from the Syndrome of depletion of mitochondrial DNA, a neurodegenerative disease that results in progressive muscle weakness and affects the vital organs such as the heart and lungs.

His parents want to bring him overseas for experimental therapy, which they say offers their son a chance of improvement.

President Donald Trump and Pope Francis both offered to provide treatment for Gard in the USA and Francis' children's hospital respectively.

The couple want a High Court judge to make a fresh analysis of their case.

Both parents interrupted proceedings and aired concerns about their son's case directly to Mr Justice Francis. The hospital also offered to send the drug to Great Ormond Street Hospital - the British hospital where Charlie is being treated - if approved, the Post added.

The pro-life organization March for Life along with a coalition of other pro-life organizations presented a petition to the hospital July 7, which urged the hospital to allow Gard's parents to take him elsewhere for treatment instead of forcing them to shut off Gard's life support.

Ms Yates added: 'It's really hard'. A United States doctor has also proposed treatment for Gard. "Independent medical experts agreed with our clinical team that this treatment would be unjustified", the hospital said.

Gard said at the hospital Sunday that there is "no evidence of catastrophic brain damage" in his son, and that the experimental treatment they are seeking can "get into the brain and help" with what harm has occurred.

Ms Gollop said GOSH had been put under "relentless pressure" in light of the global media attention on the case and that by continuing to care for Charlie, medics were giving Charlie treatment which is "detrimental" to his ruling.

The decision comes after a team of seven global medical experts alerted the hospital that fresh, unpublished data suggested that an experimental drug could improve Charlie's brain condition.

Nucleoside therapy is the experimental treatment available to Charlie in the United States but it has yet to be sufficiently tested, according to a BBC News report.

"The whole world knows about us and about Charlie and our fight".

But he rejected an attempt by the child's parents to have another judge hear the case.

Related:

Comments

Latest news

Government launches 'GST Rates Finder' App To Know New Tax Rates
Once downloaded, you will be able to see three catogories namely ' TAX rates: Goods", "TAX rates: Services' and Information @CBEC. It will be of a great help for users who want to know different rates for various goods and services under GST regime.

Honours even in NZ-Lions Test classic
The ref's initial instincts were that it was a penalty, then he spoke to his team of three and one suggested it was accidental.

USA And Universal Health Care
This is because the each state has its own different set-up on all levels socially, financially and geographically. Each state has populations equivalent to nations with universal coverage hence size can never be a limiting issue.

Voiptime Cloud Releases a Lead Management System with an Online Dialer
Online Access Voiptime Lead Management System is a cloud solution, accessible from any desktop or laptop with an internet access. When the information is spread in several sources, it is difficult to find contact needed and easy to forget important details.

Other news